Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has dosed the first participants in the next cohort of its Phase I/II UTI/Urosepsis clinical trial with RECCE® 327 (R327).
The male and female participants were dosed with R327 at 4,000mg intravenously (I.V.), at a fast infusion rate of 20 minutes, marking the highest dosage to date in this clinical trial.
R327 is an intravenous and topical therapy being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms.
The company has explored multiple infusion times of R327 within this clinical trial, testing at four fast I.V. infusion times (15, 20, 30, 45 minutes) over various dosage levels.
This latest cohort involves the highest dose (4,000mg) tested in participants in this trial, with Minimum Inhibitory Concentration (MIC) activity against bacteria already identified among existing clinical samples with this increase in dose optimisation, an important exercise for regulatory purposes.
The remaining participants are to be dosed over the coming days and the full efficacious potential of R327 via I.V. administration will be made available once the clinical trial is complete.